Bifidobacterium triple viable combined with mesalazine in treatment of patients with ulcerative colitis

Abstract

One hundred and eight patients with early onset mild or moderate active ulcerative colitis (UC) were randomly divided into combination group and control group. Patients in combination group were treated with postprandial oral mesalazine (1.0 g, q. i.d) and bifidobacterium triple viable capsule (420 mg, t. i.d) for 2 months, and those in control group were treated with postprandial oral mesalazine alone (1.0 g, q. i.d) for 2 months. Results showed that the Mayo index in combination group was significantly lower than that in control group (P=0.028) after treatment; and the clinical efficacy was significantly better than that of control group (P=0.024). After treatment, serum TNF-α, IL-6, IL-8 levels in both groups were significantly lower and IL-10 level was significantly higher (P<0.05) than those before treatment. There were significant differences in serum TNF-α, IL-6, IL-8, IL-10 levels after treatment between combination group and control group (P<0.05). After treatment, serum SOD levels were significantly reduced and MDA levels were significantly increased compared to those before treatment (both P<0.05). There were significant differences in serum SOD and MDA levels after treatment between two groups (P<0.05). Bifidobacterium triple viable combined with mesalazine shows more effective in inhibition of UC-inflammatory response and oxidative stress, resulting in reduction of UC activity and improvement of therapeutic effect. Key words: Colitis, ulcerative; Treatment